

Mounir Wz Basalus

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5749902/publications.pdf>

Version: 2024-02-01

20
papers

658
citations

687363

13
h-index

752698

20
g-index

20
all docs

20
docs citations

20
times ranked

837
citing authors

#	ARTICLE	IF	CITATIONS
1	A Randomized Controlled Trial in Second-Generation Zotarolimus-Eluting Resolute Stents Versus Everolimus-Eluting Xience V Stents in Real-World Patients. <i>Journal of the American College of Cardiology</i> , 2012, 59, 1350-1361.	2.8	229
2	Clinical Outcome Following Stringent Discontinuation of Dual Antiplatelet Therapy After 12 Months in Real-World Patients Treated With Second-Generation Zotarolimus-Eluting Resolute and Everolimus-Eluting Xience V Stents. <i>Journal of the American College of Cardiology</i> , 2013, 61, 2406-2416.	2.8	68
3	Coating irregularities of durable polymer-based drug-eluting stents as assessed by scanning electron microscopy. <i>EuroIntervention</i> , 2009, 5, 157-165.	3.2	64
4	Usefulness and safety of the GuideLiner catheter to enhance intubation and support of guide catheters: insights from the Twente GuideLiner registry. <i>EuroIntervention</i> , 2012, 8, 336-344.	3.2	57
5	Micro-computed tomographic assessment following extremely oversized partial postdilatation of drug-eluting stents. <i>EuroIntervention</i> , 2010, 6, 141-148.	3.2	33
6	Scanning electron microscopic assessment of coating irregularities and their precursors in unexpanded durable polymer-based drug-eluting stents. <i>Catheterization and Cardiovascular Interventions</i> , 2012, 79, 644-653.	1.7	26
7	Scanning electron microscopic assessment of the biodegradable coating on expanded biolimus-eluting stents. <i>EuroIntervention</i> , 2009, 5, 505-510.	3.2	24
8	Durable polymer-based stent Challenge of Promus Element versus Resolute integrity (DUTCH PEERS): Rationale and study design of a randomized multicenter trial in a Dutch all-comers population. <i>American Heart Journal</i> , 2012, 163, 557-562.	2.7	22
9	Comparison of Frequency of Periprocedural Myocardial Infarction in Patients With and Without Diabetes Mellitus to Those With Previously Unknown but Elevated Glycated Hemoglobin Levels (from the Tj ETQq1 1 0.784314 pBT /Ov		
10	Comparison of eligible non-enrolled patients and the randomised TWENTE trial population treated with Resolute and XIENCE V drug-eluting stents. <i>EuroIntervention</i> , 2012, 8, 664-671.	3.2	19
11	Polymer coatings on drug-eluting stents: Samson's hair and Achilles' heel?. <i>EuroIntervention</i> , 2013, 9, 302-305.	3.2	19
12	Benchside testing of drug-eluting stent surface and geometry. <i>Interventional Cardiology</i> , 2010, 2, 159-175.	0.0	15
13	Clinical outcome of patients with implantation of second-generation drug-eluting stents in the right coronary ostium: Insights from 2-year follow-up of the TWENTE trial. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 85, 524-531.	1.7	14
14	Effect of Oversized Partial Postdilatation on Coatings of Contemporary Durable Polymer-Based Drug-Eluting Stents: A Scanning Electron Microscopy Study. <i>Journal of Interventional Cardiology</i> , 2011, 24, 149-161.	1.2	12
15	Incidence of periprocedural myocardial infarction following stent implantation: Comparison between first- and second-generation drug-eluting stents. <i>Catheterization and Cardiovascular Interventions</i> , 2012, 80, 524-530.	1.7	10
16	Women treated with second-generation zotarolimus-eluting resolute stents and everolimus-eluting xience V stents: insights from the gender-stratified, randomized, controlled TWENTE trial. <i>Catheterization and Cardiovascular Interventions</i> , 2013, 82, 396-405.	1.7	8
17	Complex patients treated with zotarolimus-eluting resolute and everolimus-eluting xience V stents in the randomized TWENTE trial: Comparison of 2-year clinical outcome. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 85, 74-81.	1.7	7
18	Recent insights from scanning electron microscopic assessment of durable polymer-coated drug-eluting stents. <i>Interventional Cardiology</i> , 2012, 4, 661-674.	0.0	4

#	ARTICLE	IF	CITATIONS
19	On the loss of the phosphorylcholine-based DES coating on the abluminal surface of endeavor stents. Catheterization and Cardiovascular Interventions, 2010, 76, 158-159.	1.7	3
20	Clinical outcome following second-generation drug-eluting stent use for off-label versus on-label indications: insights from the two-year outcome of the TWENTE trial. EuroIntervention, 2014, 10, 664-671.	3.2	2